Kintara Therapeutics surges on pausing breast cancer trial to conserve cash

TuHURA Biosciences

19/10/2022 13:57

** Shares of drug developer Kintara Therapeutics  KTRA.O 
rise 76.6% to $0.18 before the bell
    ** Co paused REM-001 program tested in treating Cutaneous
Metastatic Breast Cancer (CMBC) to conserve cash, expecting
savings of nearly $3.0 mln through 2023  urn:newsml:reuters.com:*:nPn9BJcpTa
    ** CMBC is a type of breast cancer that occurs when cells
from a cancer in the body spread to the skin
    ** Co to use the savings to support funding of ongoing
international registrational study for VAL-083 in treating
glioblastoma (GBM), an aggressive cancer of the brain or spinal
cord
    ** KTRA says it will continue to explore ways to re-start
the planned 15-patient CMBC study program, including use of
grants from applications currently under review
    ** Co expects to read out top-line data from GBM trial
around end of 2023
    ** Stock down 80.4% YTD, as of last close
 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))